As of November 6, 2026, SpyGlass Pharma, Inc. is a publicly traded company (Nasdaq: SGP). The largest holder reporting an active stake on Schedule 13D is RA Capital, at 24.1%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Sands Frank M. (7.8%), Srinivas Akkaraju (6.3%) (Schedule 13D, February 17, 2026).
Is this your company?
About to sign with, pay or invest in SpyGlass Pharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is SpyGlass Pharma, Inc. a real, registered company?
- SpyGlass Pharma, Inc. files with the SEC under CIK 1778922 (its SEC filings).
- Its shares are listed under the ticker SGP on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Irvine, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under SpyGlassPharma, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RA Capital (filed 2026-02-17).
Who are SpyGlass Pharma, Inc.'s owners and officers?
SpyGlass Pharma, Inc.: incorporated in Delaware; business address in Irvine, California; industry Surgical & Medical Instruments & Apparatus (Schedule 13D, 2026-02-17).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-06-05)
- : Executive Officer, Director (Form D, 2025-06-05)
- : Director (Form D, 2025-06-05)
- : Director (Form D, 2025-06-05)
- : Director (Form D, 2025-06-05)
- : Director (Form D, 2025-06-05)
- : Director (Form D, 2025-06-05)
- : Director (Form D, 2025-06-05)
- : Director (Form D, 2025-06-05)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D, 2026-02-17 | Ra Capital Management, L.P. | 24.1% |
| Schedule 13G, 2026-02-17 | Srinivas Akkaraju | 6.3% |
| Schedule 13G, 2026-02-13 | Sands Frank M. | 7.8% |
| Schedule 13D, 2026-02-13 | Gilde Healthcare Holding B.V. | 6.57% |
| Schedule 13D, 2026-02-13 | New Enterprise Associates 17, L.P. | 22.2% |
| Schedule 13D, 2026-02-10 | Vensana Capital I Gp, LLC | 9.9% |
Questions about who owns SpyGlass Pharma, Inc.
Who owns SpyGlass Pharma, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of SpyGlass Pharma, Inc.: Ra Capital Management, L.P. (24.1%, Schedule 13D, filed 2026-02-17), New Enterprise Associates 17, L.P. (22.2%, Schedule 13D, filed 2026-02-13), Vensana Capital I Gp, LLC (9.9%, Schedule 13D, filed 2026-02-10), Sands Frank M. (7.8%, Schedule 13G, filed 2026-02-13) and Gilde Healthcare Holding B.V. (6.57%, Schedule 13D, filed 2026-02-13); 1 more is listed above.
Who are the largest shareholders of SpyGlass Pharma, Inc.?
By the share each holder's latest filing reports, the largest holders of SpyGlass Pharma, Inc. on this page are Ra Capital Management, L.P. (24.1%), New Enterprise Associates 17, L.P. (22.2%) and Vensana Capital I Gp, LLC (9.9%).
When did Ra Capital Management, L.P. buy into SpyGlass Pharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13D, filed 2026-02-17, reporting 24.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on SpyGlass Pharma, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on SpyGlass Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on SpyGlass Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own SpyGlass Pharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 7,392,301 shares (22.1% of shares outstanding), held indirectly through a see note 3 (Form 4, 2026-02-11).
- , a 10% owner: 7,392,301 shares (22.1% of shares outstanding), held indirectly through a see note 2 (Form 4, 2026-02-11).
- , a 10% owner: 7,392,301 shares (22.1% of shares outstanding), held indirectly through a see note 3 (Form 4, 2026-02-11).
- , a 10% owner: 7,392,301 shares (22.1% of shares outstanding), held indirectly through a see note 2 (Form 4, 2026-02-11).
- , a 10% owner: 7,392,301 shares (22.1% of shares outstanding), held indirectly through a see note 2 (Form 4, 2026-02-11).
Shares outstanding: 33,447,979 as of 2026-07-29, from the company's latest SEC cover page.
How much has SpyGlass Pharma, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-06-05 | $75M | $75M |
| Form D, 2023-07-11 | $40.01M | $90.02M |
Latest IPO step: SpyGlass Pharma, Inc. filed its final IPO prospectus, ticker SGP (424B4, 2026-02-06).
IPO filings: 424B4, 2026-02-06, S-1/A, 2026-01-29, S-1, 2026-01-16; ticker SGP on Nasdaq Global Select Market.
Keep reading
More on SpyGlass Pharma, Inc. and the records around it.
SpyGlass Pharma, Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
- Form D filing Jun 2025
Companies that share a holder
- Gilde Healthcare Holding B.V. also filed stake reports on 2 other companies: Shoulder Innovations, Inc. (Aug 2026), Mobia Medical, Inc. (May 2026)
- New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Monte Rosa Therapeutics, Inc. (Jul 2026), Inventiva S.A. (Apr 2026), Korro Bio, Inc. (Mar 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/spyglass-pharma